South Dakota § 34-20B-16 Substances included in Schedule II.

South Dakota Statutes

§ 34-20B-16 — Substances included in Schedule II.

South Dakota § 34-20B-16

Title 34PUBLIC HEALTH AND SAFETY

Ch. 34-20DRUGS AND SUBSTANCES CONTROL

This text of South Dakota § 34-20B-16 (Substances included in Schedule II.) is published on Counsel Stack Legal Research, covering South Dakota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

S.D. Codified Laws § 34-20B-16 (2026).

Text

Any of the following substances, including their salts, isomers, and salts of isomers, is included in Schedule II except those narcotic drugs listed in other schedules, whether produced directly or indirectly by extraction from substances of vegetable origin, independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:

(1)Opium (except when it meets the requirements of subdivision 34-20B-23 (7) or 34-20B-26 (5)), coca leaves, and opiate;

(2)Any salt, compound, derivative, or preparation of opium, coca leaves (including cocaine), or opiate, excluding apomorphine, dextrorphan, naloxone, naloxegol, naldemedine, nalbuphine, nalmefene, naltrexone, 6ß-naltrexol, and samidorphan;

(3)Any salt, compound, derivative, or preparation thereof that

Free access — add to your briefcase to read the full text and ask questions with AI

Any of the following substances, including their salts, isomers, and salts of isomers, is included in Schedule II except those narcotic drugs listed in other schedules, whether produced directly or indirectly by extraction from substances of vegetable origin, independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (1) Opium (except when it meets the requirements of subdivision 34-20B-23 (7) or 34-20B-26 (5)), coca leaves, and opiate; (2) Any salt, compound, derivative, or preparation of opium, coca leaves (including cocaine), or opiate, excluding apomorphine, dextrorphan, naloxone, naloxegol, naldemedine, nalbuphine, nalmefene, naltrexone, 6ß-naltrexol, and samidorphan; (3) Any salt, compound, derivative, or preparation thereof that is chemically equivalent or identical with any of the substances referred to in subdivisions (1) and (2), except that these substances may not include decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine; and may not include the isoquinoline alkaloids of opium; (4) Opium poppy and poppy straw; (5) Amphetamine; (6) Methamphetamine; (7) Amobarbital; (8) Pentobarbital; (9) Secobarbital; (10) Methylphenidate; (11) Phenmetrazine; (12) Etorphine; (13) Diprenorphine; (14) Deleted by SL 2000, ch 170, § 1; (15) Nabilone; (16) Glutethimide; (17) Phencyclidine immediate precursors: (a) 1-phenylcyclohexylamine; (b) 1-piperidinocyclohexanecarbonitrile (PCC); (18) Lisdexamfetamine, its salts, isomers, and salts of its isomers; (19) Tapentadol; and (20) Dronabinol [(-)-delta-9-trans tetrahydrocannabinol] in an oral solution in a drug product approved for marketing by the United States Food and Drug Administration.

Legislative History

SL 1970, ch 229, § 8 (b) (1); SDCL Supp, § 39-17-59; SL 1977, ch 315, § 4; SL 1978, ch 249, § 1; SL 1981, ch 13, § 9; SL 1981, ch 261, § 1; SL 1985, ch 278, § 51; SL 1986, ch 284; SL 1987, ch 255, § 3; SL 1992, ch 245, § 1; SL 1993, ch 247, § 2; SL 2000, ch 170, § 1; SL 2008, ch 170, § 1, eff. Feb. 13, 2008; SL 2010, ch 174, § 2, eff. Feb. 24, 2010; SL 2012, ch 183, § 2, eff. Feb. 23, 2012; SL 2015, ch 180, § 2, eff. Feb. 18, 2015; SL 2016, ch 175, § 3, eff. Feb. 18, 2016; SL 2018, ch 203, § 3, eff. Feb. 8, 2018; SL 2021, ch 144, § 4, eff. Feb. 17, 2021; SL 2022, ch 109, § 3, eff. Feb. 9, 2022.